Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huzhang Jiedu Keli (虎杖解毒颗粒) is a Traditional Chinese Medicine (TCM) formulation primarily composed of *Polygonum cuspidatum* (Huzhang). It is recognized for its potent anti-inflammatory and antiviral properties, largely attributed to its high content of resveratrol and polydatin. The drug was notably included in Chinese clinical guidelines as a recommended treatment for COVID-19 to manage inflammatory responses and viral symptoms. Beyond its use in infectious diseases, Huzhang Jiedu Keli has been investigated as an adjuvant therapy in oncology, specifically for its potential to modulate the ecological niche microenvironment in patients with liver metastasis from colorectal cancer. It is typically administered orally in a granule form.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Huzhang Jiedu Keli.